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Cognitive fatigue in multiple sclerosis is
associated with alterations in the functional
connectivity of monoamine circuits
Mara Cercignani,1,2,* Ottavia Dipasquale,3 Iulia Bogdan,1 Tiziana Carandini,4
James Scott,1 Waqar Rashid,1 Osama Sabri,5 Swen Hesse,5,6 Michael Rullmann,5,6
Leonardo Lopiano,7 Mattia Veronese,3 Daniel Martins3 and Marco Bozzali1,7
Fatigue is a highly prevalent and debilitating symptom in multiple sclerosis, but currently the available treatment options have lim-
ited efficacy. The development of innovative and efficacious targeted treatments for fatigue in multiple sclerosis has been marred
by the limited knowledge of the underlying mechanisms. One of the hypotheses postulates that multiple sclerosis pathology might
cause reduced monoaminergic release in the central nervous system with consequences on motivation, mood and attention. Here,
we applied the recently developed Receptor-Enriched Analysis of Functional Connectivity by Targets method to investigate whether
patients with high and low fatigue differ in the functional connectivity (FC) of the monoamine circuits in the brain. We recruited
55 patients with multiple sclerosis, which were then classified as highly fatigued or mildly fatigued based on their scores on the cog-
nitive sub-scale of the Modified Fatigue Impact scale. We acquired resting-state functional MRI scans and derived individual maps
of connectivity associated with the distribution of the dopamine, noradrenaline and serotonin transporters as measured by positron
emission tomography. We found that patients with high fatigue present decreased noradrenaline transporter (NAT)-enriched con-
nectivity in several frontal and prefrontal areas when compared to those with lower fatigue. The NAT-enriched FC predicted nega-
tively individual cognitive fatigue scores. Our findings support the idea that alterations in the catecholaminergic functional circuits
underlie fatigue in multiple sclerosis and identify the NAT as a putative therapeutic target directed to pathophysiology.
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Abbreviations: 5-HT ¼ serotonin; BICAMS ¼ Brief International Cognitive Assessment for multiple sclerosis; BOLD ¼ blood
oxygenation level dependent; BVMTR ¼ Brief Visuospatial Memory Test Revised; DA ¼ dopamine; DAT ¼ dopamine transporter;
DMTs ¼ disease-modifying treatments; EDSS ¼ expanded disability status score; ESS ¼ Epworth Sleepiness Scale; FC ¼ functional
connectivity; FLAIR ¼ fluid-attenuated inversion recovery; fMRI ¼ functional MRI; HADS-D ¼ Hospital Anxiety and Depression
Scale; HS ¼ healthy subjects; ICA ¼ independent component analysis; MFIS ¼ modified fatigue impact scale; MFIS-Cog ¼
Cognitive subscale of the Modified Fatigue Impact Scale; NA ¼ noradrenaline; NAT ¼ noradrenaline transporter; NAT ¼ nor-
adrenaline transporter; OC ¼ optimally combined; PET ¼ positron emission tomography; PFC ¼ prefrontal cortex; REACT ¼
Receptor-Enriched Analysis of Functional Connectivity by Targets; ROC ¼ receiver operating discrimination; rs-fMRI ¼ resting-
state fMRI; SDMT ¼ Symbol Digit Modalities Test; SERT ¼ serotine transporter; SPECT ¼ single-photon emission computerized
tomography; TE ¼ echo time; TFCE ¼ threshold-free cluster enhancement; TI ¼ inversion time; TR ¼ repetition time.
Introduction
Fatigue is a highly prevalent and disabling symptom in
multiple sclerosis,1 with a strong impact on patients’
quality of life.2 Cognitive fatigue is a subjective symptom
that is typically described by patients with multiple scler-
osis as a chronically present ‘mental fog’ that reduces
their performance, especially—but not only—in job-
related activities.3 The underlying mechanisms of chronic
fatigue in multiple sclerosis remain largely unknown, but
seem decoupled from acute neuroinflammatory episodes,4
which makes the management of fatigue particularly
challenging.
The pathophysiology of fatigue in multiple sclerosis is
still largely unknown, though different underlying
mechanisms have been proposed so far.5 Growing evi-
dence supports the role of aberrant monoaminergic
neurotransmission.5,6 Monoamines are crucial modulators
of functions such as motivation, mood and attention,
which are all reduced in multiple sclerosis patients with
fatigue. Different combinations of grey and white matter
damage, which are typically observed in multiple scler-
osis, might account for different patterns of chronic
fatigue and inter-subject variability in response to thera-
pies.7 First, both focal (i.e. brainstem monoaminergic nu-
clei where monoaminergic neurons are located) and
diffuse grey matter pathology (i.e. cortical neurons) may
reduce monoamine release or lead to poor responsiveness
of neuronal targets, located mainly in the prefrontal
cortex (PFC).8–10 Secondly, the disconnection between
brainstem monoaminergic nuclei and target areas due to
macro- or microscopic white matter damage may result
in reduced monoaminergic release in the brainstem nuclei
and/or in their projective white matter tracts.5 Third, in-
flammation may decrease monoamine synthesis or alter
their function,11 thus lowering the neurotransmitter sup-
ply to the rest of the brain and possibly leading to a
functional reorganization of central cortical networks.12,13
Among monoamines, a dopamine (DA) imbalance is
generally considered as one of the culprits of chronic
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fatigue in multiple sclerosis.6 Supporting this idea, the
two most commonly used drugs to improve fatigue in
multiple sclerosis—amantadine and methylphenidate—en-
hance dopaminergic transmission. Although generally well
tolerated, the efficacy of these drugs is limited.7 Hence,
identifying new therapeutic targets to improve fatigue in
multiple sclerosis patients remains as an unmet clinical
need. This task has nevertheless been marred by the cur-
rent lack of understanding of precise brain mechanisms
underlying fatigue in multiple sclerosis.
While DA alterations are typically evoked to account
for fatigue in multiple sclerosis, other neurochemical sys-
tems, such as noradrenaline (NA), have equally been
hypothesized to contribute to fatigue more generally. The
role of NA in fatigue has been investigated only in one
study in Parkinson’s disease, but no significant correla-
tions were identified between the extent of degeneration
of the locus coeruleus—where NA is mainly synthe-
tized—and the degree of fatigue.14 Nevertheless, the locus
coeruleus projects diffusely to the entire brain (mostly
PFC and cingulum) and takes a primary part in the
ascending arousal system modulating arousal and atten-
tion.10 Moreover, the locus coeruleus regulates other
higher-level cognitive processes such as working memory,
motivation, pain and autonomic reflexes.15 Interestingly,
the abovementioned drugs used to treat fatigue in
multiple sclerosis are not selective for DA transmission,
but also enhance NA neurotransmission. Hence, while
the role of NA circuits in fatigue in multiple sclerosis has
been largely overlooked, it is plausible that NA circuits
may equally contribute to the genesis of fatigue and
response to treatment.
Finally, preliminary studies have also suggested that a
dysregulation of the serotoninergic system [serotonin (5-
HT)] might contribute to the pathophysiology of fatigue
in multiple sclerosis.16 In the more general context of
fatigue (i.e. not restricted to multiple sclerosis), positron
emission tomography (PET) studies have demonstrated
altered 5-HT transporter distribution in patients with
chronic fatigue syndrome as compared to controls, as
well as in patients with Parkinson’s disease complaining
of fatigue as compared to those without fatigue.17,18 One
study using PET imaging to assess the availability of 5-
HT transporters in multiple sclerosis patients when com-
pared to controls reported a lower availability in the lim-
bic and paralimbic regions of multiple sclerosis patients
and higher availability in their frontal cortex.19 The same
study also found a positive association between 5-HT
transporters availability in the insula of multiple sclerosis
patients and both their depression and fatigue scores.19
The neural substrates of fatigue in multiple sclerosis
have been mostly studied using functional MRI (fMRI).
Reduced connectivity between the basal ganglia and the
PFC in multiple sclerosis patients with fatigue remains as
the most consistent finding in task-related and resting-
state fMRI (rs-fMRI) studies (for a review, see ref.6).
This circuit alteration has been suggested to mostly reflect
decreases in DA neurotransmission in multiple sclerosis
patients with fatigue based on the known anatomy of the
DA pathways. However, as fMRI has no intrinsic select-
ivity to any specific neurochemical target, gaining insight
about the neurochemical mechanisms underlying function-
al alterations during disease based solely on fMRI is
challenging at best. Ultimately, this technical limitation
makes it impossible to guide the selection of drugs that
most likely can address functional alterations as detected
by fMRI.
Here, we applied the recently developed Receptor-
Enriched Analysis of functional Connectivity by Targets
(REACT)20 framework to rs-fMRI data acquired in a
cohort of multiple sclerosis patients with high and low
fatigue to investigate how changes in resting state func-
tional connectivity (FC) often reported in multiple scler-
osis patients with fatigue relate to the distribution of the
dopamine (DAT), noradrenaline (NET) and serotonin
(SERT) transporters. REACT is a multimodal approach
that enriches the rs-fMRI analysis with information about
the spatial distribution density of molecular targets
derived from PET imaging and allows to investigate
changes in FC associated with specific molecular targets.
We hypothesized that some, if not all, of these transport-
er-enriched FC maps would show reductions in multiple
sclerosis patients with higher cognitive fatigue compared
to those with lower fatigue.
Materials and methods
Participants and study design
Seventy-one patients with relapsing-remitting multiple
sclerosis were recruited from the multiple sclerosis clinic
of Brighton and Sussex Universities Hospitals Trust, UK,
between April 2017 and May 2018 into a larger study
on multiple sclerosis fatigue. At recruitment, exclusion
criteria for patients were history of other neurological
diseases, or the presence of psychiatric and other clinical
conditions. The depression subscale of the Hospital
Anxiety and Depression Scale (HADS-D) and the
Epworth Sleepiness Scale (ESS) were used to exclude par-
ticipants with evidence of depression and sleep disorders
at the suggested cut-off of 11 and 10, respectively.21,22
Participants on treatment with hypnotics within the last
4 weeks prior enrolment, on recreational drugs, or with a
known alcohol abuse were excluded. Major abnormal-
ities, such as anaemia, ongoing infections, thyroid dys-
function, vitamin deficiencies, sleep disturbances including
obstructive sleep apnoea were excluded based on the
blood tests performed for clinical purposes. The Brief
International Cognitive Assessment for multiple sclerosis
(BICAMS23) was used to screen for cognitive impairment.
For this particular study, we also excluded patients on
treatment with compounds acting on one or more of the
molecular systems of interest (DA, noradrenaline,
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serotonin). Ethical approval was obtained from the
London-Surrey Borders Research Ethics Committee (refer-
ence¼ 17/LO/0081). Written informed consent was
obtained from all participants according to the declar-
ation of Helsinki.
Fatigue was assessed using the Modified Fatigue Impact
Scale (MFIS). The total MFIS score (MFIS-Tot; ranging
0–84) is the sum of the cognitive (MFIS-Cog), physical
and psychosocial subscales. Here, we focused on MFIS-
Cog. Patients were split into two groups (highly fatigued
and mildly fatigued) based on their MFIS-Cog score,
using the group median value as discriminator.
Neuroimaging
MRI data were acquired on a 1.5 T Siemens Magnetom
Avanto scanner (Siemens Healthineers, Erlangen,
Germany) at the Clinical Imaging Sciences Centre of the
University of Sussex, UK. The examination included:
volumetric T1-weighted MPRAGE [echo time
(TE)¼ 3.57 ms; repetition time (TR)¼ 27.30 ms; inversion
time (TI)¼ 100ms; flip-angle¼ 70; field of view¼ 256 
240 mm2; matrix¼ 254  40; slice-thickness¼ 1 mm]
and T2*-weighted multi-echo echo-planar imaging24 for
rs-fMRI (TR ¼ 2570 ms; TE ¼ 15, 34, 54 ms; flip-angle
¼ 90; resolution ¼ 3.7  3.75  4.49 mm; matrix-size
¼ 64  64; 31 axial slices; 185 volumes). T2-weighted
and fluid-attenuated inversion recovery (FLAIR) scans
were acquired for the purpose of identifying and quanti-
fying white matter lesions. In addition, multi-shell diffu-
sion-weighted MRI and quantitative magnetization
transfer MRI were collected, but were not used in this
study. White matter lesions were identified on FLAIR
scans by two observers, and measured with local thresh-
olding segmentation (Jim v.7, Xinapse Systems,
Colchester, UK).
The rs-fMRI dataset was pre-processed using AFNI25
and FMRIB Software Library (FSL). Pre-processing steps
included volume re-alignment, time-series de-spiking and
slice time correction. After the pre-processing, functional
data were optimally combined (OC) by taking a weighted
summation of the three echoes using an exponential T2*
weighting approach.26 The OC data were then de-noised
with the multi-echo independent component analysis
(ME-ICA) approach implemented in AFNI by the tool
meica.py (Version v2.5).27,28 ME-ICA has proved a
greater efficacy in detecting and removing motion arte-
facts compared to other modalities developed for single-
echo data, while preserving the blood-oxygen level-de-
pendent (BOLD) signal.29 White matter and cerebrospinal
fluid signals were regressed out and a high-pass temporal
filter with a cut-off frequency of 0.005 Hz was applied.
Data were normalized into standard space, smoothed
with an 8 mm3 Gaussian kernel and resampled at 2 2
 2 mm resolution.
For the analysis with REACT, we used molecular tem-
plates of the DAT, NET and SERT systems. The DAT
map is a publicly available template of 123I-Ioflupane sin-
gle-photon emission computerized tomography (SPECT)
images (https://www.nitrc.org/projects/spmtemplates) from
30 healthy subjects (HS) without evidence of nigrostriatal
degeneration.30 The NET atlas was obtained by averaging
the [11C]MRB PET brain parametric maps from an inde-
pendent dataset of 10 HS (33.3 6 10 years, four
women).31 The SERT atlas is a publicly available tem-
plate32 of [11C]DASB PET images of 210 healthy controls
from the Cimbi database.33
All molecular atlases were normalized by scaling the
image values between 0 and 1, although preserving the
original intensity distribution of the images, and masked
using a standard grey matter mask. Of note, for each
atlas, we masked out the regions that were used as refer-
ences for quantification of the molecular data in the kin-
etic models for the radioligands, namely the occipital
areas for DAT and NET and the cerebellum for SERT.
Finally, we resampled the SERT image in order to have
all atlases in standard MNI space with 2 mm3 voxel size.
Details of REACT methodology can be found else-
where.20 In brief, the functional circuits related to the
DAT, NET and SERT systems were estimated using a
two-step multivariate regression analysis34,35 implemented
with the fsl_glm command of FSL. This analysis is con-
ceptually comparable to the approach also known as
dual regression, used in rs-fMRI to investigate the FC of
the resting state networks. In the first step, the rs-fMRI
volumes were masked using a binarized atlas derived
from the molecular data to restrict the analysis to the
voxels for which the transporter density information was
available in the template. Then, the molecular templates
were used as a set of spatial regressors to weight the rs-
fMRI images and estimate the dominant BOLD fluctu-
ation related to each molecular system at the subject
level. Those subject-specific time series were then used as
temporal regressors in a second multivariate regression
analysis to estimate the subject-specific spatial map asso-
ciated with each molecular atlas. The output consists of
three maps per participant (one for each monoamine
transporter system) reflecting the transporter-enriched FC.
At this stage, the analysis was conducted on the whole
grey matter volume. Both data and the design matrix
were demeaned (–demean option); the design matrix col-
umns were also normalised to unit standard deviation
with the –des_norm option.34
Statistical analysis
The subject-specific target-enriched spatial maps were
compared between the two groups using permutation
tests. We applied cluster-based inference within random-
ise,36 using 5000 permutations per test and contrast.
Two contrasts were used for every kind of map, in order
to test for both increases or decreases in connectivity
with fatigue. A cluster was considered significant if PFWE
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< 0.05, corrected for multiple comparisons using the
threshold-free cluster enhancement (TFCE) option.37
Next, we extracted the mean FC value from the clus-
ters showing a significant between-group difference and
assessed their correlation with the individual MFIS-Cog
scores. Furthermore, to gain insight about how well the
transporter-enriched FC would perform in discriminating
between highly fatigued and mildly fatigued multiple
sclerosis patients, we also used the average of the FC val-
ues from the cluster showing the strongest association
with fatigue in a receiver operating discrimination (ROC)
analysis to calculate the sensitivity and specificity of this
target-enriched FC-based discrimination.
Data availability
MRI data are available from the corresponding author
upon reasonable request, providing signature of an ap-
propriate data transfer agreement. REACT is based on




Two patients did not complete the MRI session and were
thus excluded. Further 14 patients were excluded from
the analysis because of concomitant treatment with medi-
cations that could confound DAT-, NET- and SERT-
related FC connectivity (amantadine, N¼ 3; amitriptyline,
N¼ 4; citalopram, N¼ 4; mirtazapine, N¼ 1; quetiapine,
N¼ 1; sertraline, N¼ 4; venlafaxine, N¼ 1). The mean
age of the remaining 55 patients was 42.5 (SD¼ 7.8)
years, their median expanded disability status (EDSS)
score was 1.5 (range¼ 0–6), and their mean HADS-D
was 2.18 (SD¼ 2.19).
The median MFIS-Cog score was 15. Based on this
value, all patients with MFIS-Cog >15 were allocated
to the cognitively highly fatigued group (N¼ 26), leav-
ing 29 in the cognitively mildly fatigued group. With
the exception of two patients in the highly fatigued
group and eight in the mildly fatigued group, all
other patients were under disease-modifying treatment
(DMTs) (Alemtuzumab: N¼ 13, Dimetylfumarate:
N¼ 9, Natalizumab: N¼ 8, Teriflunomide: N¼ 4,
Glatiramer Acetate: N¼ 4, Fingolimod: N¼ 4, Beta-
interferons: N¼ 3). The distribution of DMTs for the
two groups did not differ according to a Chi-squared
test (P-value¼ 0.15). Table 1 summarizes the main
demographic and clinical variables for the two groups.
The mean Symbol Digit Modalities Test (SDMT) and
Brief Visuospatial Memory Test Revised (BVMTR)
scores were significantly lower (P¼ 0.04 and P¼ 0.05,
respectively) in the fatigued when compared to the non-
fatigued group. The median EDSS score, the mean
HADS-D and the mean lesion volume were instead sig-
nificantly higher in patients with fatigue. Hence these
three variables were added as covariates to the main
group comparison analysis. No between-group differen-
ces were observed for any other variables.
Multiple sclerosis patients with high
fatigue present decreased frontal
NET-enriched functional
connectivity
Figure 1 shows the molecular maps used in the dual re-
gression and the corresponding population-averaged mo-
lecular-enriched FC maps. Note that the molecular
templates have been rescaled between 0 and 1.






M/F 11/14 9/21 0.28a
Mean Age (SD) 41.9 (8.1) 43.1 (7.6) 0.6
Median EDSS (range) 2.5 (0–6) 1.25 (0–6) 0.005b
Mean SDMT (SD) 45.00 (11.5) 51.17 (9.74) 0.04
Mean BVMTR (SD) 23.84 (7.34) 27.21 (5.14) 0.05
Mean CVLT (SD) 54.52 (10.18) 55.89 (11.77) 0.65
Median ESS (range) 5 (0–9) 4 (0–10) 0.4b
Mean HADS-D (SD) 2.84 (2.36) 1.65 (1.67) 0.04
Mean lesion volume (SD) (ml) 13.46 (11.82) 8.09 (5.16) 0.03
Mean MFIS-Cog (SD) 22.4 (5.2) 10.5 (3.8) <0.0001
Statistical comparisons were performed using an independent sample T-test, unless otherwise specified. Boldafce values indicate statistically significant between-group differences.
a Chi-square test.
b Wilcoxon Rank Sum test.
BVMTR ¼ Brief Visuospatial Memory Test Revised; CVLT ¼ California verbal learning test II; EDSS ¼ expanded disability status score; ESS ¼ Epworth Sleepiness Scale; F ¼ female;
HADS-D ¼ Depression subscale of the Hospital anxiety and depression scale; M ¼ male; MFIS-Cog ¼ Cognitive subscale of the Modified Fatigue Impact Scale; SD ¼ standard devi-
ation; SDMT ¼ symbol digit modalities test.
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We did not find any differences between groups in the
DAT-enriched and SERT-enriched maps. By contrast, we
found four clusters around the mid-section in the paracin-
gulate gyrus, and in the left hemisphere in the frontal
pole, inferior frontal gyrus pars triangularis, and middle
frontal gyrus where NET-enriched FC was significantly
reduced (P< 0.05, TFCE-corrected) in highly fatigued
patients compared to mildly fatigued (Fig. 2).
NET-enriched functional
connectivity predicts inter-individual
variation in cognitive fatigue scores
NET-enriched connectivity values from the four clusters
shown in Fig. 2 predicted negatively the MFIS-Cog scores
(Fig. 3). The univariate correlation was significant for the
four clusters (correlation coefficients ranging from 0.16
Figure 1 Receptor-Enriched Analysis of Functional Connectivity by Targets (REACT). PET maps used to inform REACT (left) and the resulting
target-enriched functional connectivity maps, averaged across the whole study sample (right). The maps are overlaid onto the T1-weighted
template in MNI space available with FSL. Note that the molecular templates have been rescaled between 0 and 1.
Figure 2 Areas of reduced noradrenaline transporter (NET)-enriched functional connectivity in multiple sclerosis patients with cognitive
fatigue compared to those without. The colour scale represents the P-value (after correction for multiple comparisons). The thresholded
statistical map is overlaid onto the MNI T1-weighted template available with FSL. The x, y, z values indicate the MNI coordinates of the
displayed slices.
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to 0.5; P values ranging from 0.03 to 5  104).
However, a stepwise linear regression analysis suggested
that the best model to explain MFIS-Cog was provided
by a single regressor including NET-related connectivity
in the frontal pole (coefficient ¼ 0.42, P¼ 0.0005),
with F¼ 13.79, R2 ¼ 0.21.
Frontal NET-enriched functional
connectivity discriminates between
multiple sclerosis patients with high
and low cognitive fatigue with good
sensitivity/specificity
In order to explore the ability of NET-enriched FC to dis-
criminate between patients with high and low cognitive
fatigue, we computed the ROC curve, varying the discrimi-
nating value of the FC of the frontal pole cluster between
28 and 12. The resulting curve (Fig. 4) suggests that a
specificity of 0.83 could be achieved with a sensitivity just
around 0.76, obtained using a FC threshold of 4.2.
Discussion
In response to the current lack of clarity about the brain
mechanisms underlying fatigue in multiple sclerosis, here
we used a novel multimodal approach to investigate
changes in the FC measured at rest associated with the
DAT, NET and SERT circuits in multiple sclerosis
patients with high fatigue as compared to those with
lower levels of fatigue. Our main finding was a reduced
pattern of NET-enriched FC within prefrontal cortical
areas and the anterior paracingulate cortex in multiple
sclerosis patients with high fatigue. Notably, the NET-
enriched FC from clusters showing significant group
differences could negatively predict individual MFIS-cog
scores. Moreover, NET-enriched FC could discriminate
between highly fatigued and mildly fatigued patients with
good sensitivity and specificity.
Although no single cause for fatigue in multiple
sclerosis has been identified, growing evidence supports a
contribution of DA imbalance in the mesocortical path-
way.5,6 This hypothesis stems from two empirical obser-
vations: (i) fMRI studies reported decreased connectivity
between the basal ganglia and the PFC, two key-hubs of
the dopaminergic mesocortical pathway38,39; (ii) drugs
currently used in the treatment of fatigue in multiple
sclerosis, such as amantadine and methylphenidate, en-
hance the DA neurotransmission and have been shown to
reduce fatigue—although with limited efficacy. However,
given the lack of intrinsic affinity of the BOLD signal for
specific neurotransmitters, all previous fMRI studies could
Figure 3 Association between noradrenaline transporter (NET)-enriched functional connectivity and inter-individual variation in cognitive
fatigue scores. Scatterplots depicting negative correlations between cognitive fatigue scores and the noradrenaline transporter-enriched
functional connectivity for the four clusters identified in the whole-brain analysis. Cog-MFIS ¼ cognitive subscale of the modified fatigue impact
scale; L ¼ left.
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not shed light on the neurochemical systems specifically
involved in the functional alterations detected in the brain
of multiple sclerosis patients with high fatigue.
Our study shows for the first time that multiple scler-
osis patients with high fatigue as compared to those with
low fatigue show decreased connectivity in NET-related
functional circuits, which we suggest might play a
pivotal role in the genesis of fatigue in these patients.
Importantly, these group differences on FC emerged
beyond group differences on depressive symptoms, lesion
load or disability, which are important confounds in
studies of fatigue in multiple sclerosis. Furthermore, they
cannot be explained by significant differences in DMTs
distribution and average anatomical distribution of white
matter lesions or any obvious brainstem lesion suggestive
of a focal involvement of either the ventral tegmental
area or the locus coeruleus between the two groups of
patients. By contrast, we found no evidence of SERT-
related FC abnormalities.16
At a first glance, our findings appear in direct contrast
with the DA imbalance hypothesis of fatigue in multiple
sclerosis. Indeed, we did not find any group differences
in DAT-related FC. However, we should acknowledge
that the complex biology of the NET does not allow us
to exclude a contribution of DA for our findings. Indeed,
the NET participates in the reuptake of both DA and
NA and does so with higher affinity for DA than NA in
the regions of the brain where DAT expression is low
(such as in the frontal areas we found in this study).40,41
Hence, it is highly plausible that the decreases in
NET-related FC in the frontal regions of the brain of
multiple sclerosis patients with high fatigue reported here
may reflect alterations in both DA and NA neurotrans-
mission. This pattern of changes fits well with the
hypothesis of disconnection in the projection pathways of
both noradrenergic and dopaminergic systems in multiple
sclerosis. Furthermore, these alterations match the known
pharmacology of the drugs used to treat fatigue in
multiple sclerosis, i.e. amantadine, methylphenidate and
modafinil, which enhance both DA and NA neurotrans-
mission. Finally, we note that frontal noradrenergic trans-
mission has also been suggested to participate in the
regulation of cognitive processes highly relevant in the
context of fatigue, such as motivation.42,43
Our findings come with some important implications
for the treatment of fatigue in multiple sclerosis. First, we
provide mechanistic insights that support the rationale of
using catecholamine-directed drugs to improve fatigue in
multiple sclerosis as informed by physiopathology. For
now, it is unclear whether the therapeutic effects of these
drugs should be attributed to DA, NA or both. Based on
our findings, we hypothesize that drugs such as amantadine
or methylphenidate might improve fatigue in multiple scler-
osis by inhibiting NET reuptake of both NA and DA in
frontal circuits. Supporting this idea, in one in vitro study
amantadine was shown to be about 30 times more potent
in inhibiting NET than DAT.44 Although our study cannot
clarify the mechanisms underlying treatment effects for these
drugs, we showcase a useful framework to investigate such
effects in future randomized, placebo-controlled, pharmaco-
imaging studies.
Second, the decreased NET-related FC we report here
suggests that specific inhibitors of NET reuptake, such as
atomoxetine, might be of value in treating fatigue in mul-
tiple sclerosis. As far as we know, NET inhibitors have
never been thoroughly investigated in the context of fa-
tigue in multiple sclerosis. Only one open-label study in
depression found that adjunctive atomoxetine improved
residual fatigue.45 Drugs such as atomoxetine have dis-
tinct advantages over stimulants such as methylphenidate.
Since atomoxetine does not affect dopaminergic neuro-
transmission in the basal ganglia, it is presumed to cause
less anxiety, fewer motor disturbances and less potential
for dependence.46 This hypothesis should be investigated
in future clinical trials examining the clinical efficacy of
NET inhibitors for fatigue symptoms in multiple sclerosis.
Third, given that we did not find any group differences
on SERT-related FC, our findings suggest that drugs
specifically targeting the SERT (i.e. selective serotonin re-
uptake inhibitors SSRIs) are unlikely to offer any promise
in addressing primary fatigue in multiple sclerosis. Of
course, this should not devalue the use of these drugs for
addressing other psychiatric comorbidities, such as anx-
iety or depression. However, our findings concur with
the idea that if an antidepressant is required for multiple
sclerosis patients with fatigue, then dual reuptake inhibi-
tors increasing both 5-HT and NA (i.e. venlafaxine) or
Figure 4 Frontal noradrenaline transporter (NET)-enriched
functional connectivity discriminates between multiple sclerosis
patients with and without fatigue. Receiver operating characteristic
(ROC) curve for the classification of multiple sclerosis patients with
and without fatigue based on the average NET-enriched functional
connectivity (FC) from the significant cluster in the frontal pole.
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NA and DA (i.e. buproprion) levels might offer some
advantages over SSRIs to concomitantly improve primary
fatigue.
This study also comes with some limitations. First of
all, although REACT improves the specificity of FC ana-
lysis, the approach remains relatively indirect and relies
on molecular templates estimated in independent cohorts
of healthy individuals. Therefore, further specification
from intra-regional variation across patients is not pos-
sible using the current dataset as it would require PET
data for each ligand and patient. The availability of PET
data from the same cohort of patients would allow the
creation of patient-specific templates, which might en-
hance the accuracy of the maps of FC related to each
target. This should be examined in future studies validat-
ing our work further. Secondly, cognitive fatigue is an ill-
defined concept that can only be measured using self-
reported scores. We explored the diagnostic ability of
NET-enriched FC by computing the ROC curve and
found that NET-enriched FC offers good sensitivity and
specificity in discriminating between highly fatigued and
mildly fatigued patients in our cohort. Hence, NET-
enriched FC could offer a putative quantitative biomarker
to identify multiple sclerosis patients with high fatigue
and monitor treatment response. However, the validity of
this analysis is limited by the use of the same sample for
validation and testing and should be revisited in future
studies using independent cohorts. Third, fatigue is often
comorbid with other neuropsychiatric symptoms, such as
apathy, depression or sleep disturbances. These other
symptoms are important confounds in studies of fatigue
in multiple sclerosis. To mitigate any potential bias, the
inclusion/exclusion criteria in the present research were
reasonably strict to minimise the impact of depression
and sleep disturbance. Despite this, the highly fatigued
group had a significantly lower average HADS-D score
than the mildly fatigued group. We minimized this poten-
tial bias by adjusting all our analyses for HADS-D.
Similarly, patients with high fatigue were, on average,
more disabled and had larger lesion volume than the
mildly fatigued group; hence, we also included these vari-
ables as covariates of no-interest. Finally, cognitive im-
pairment was carefully checked by using the BICAMS
battery. Some significant differences at the group level
(P¼ 0.04) were present in the SDMT, but only six
patients scored below the cut-off of 38.
In conclusion, our study supports the involvement of
decreased frontal catecholaminergic connectivity, particu-
larly that involving the NET, in the pathogenesis of cog-
nitive fatigue in multiple sclerosis. Our findings provide
further rationale for using catecholamine-enhancing drugs
to treat fatigue in multiple sclerosis and uncovered a
symptom-related brain mechanism through which current
drugs might exert their therapeutic effects. Furthermore,
we also identify NET as a putative therapeutic target
directed to physiopathology, an observation that sets
grounds for future trials to investigate the efficacy of
specific NET reuptake inhibitors, such as atomoxetine,
for fatigue in multiple sclerosis.
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